Global R&D Pipeline
My Favorite
Hot Targets:
Tau
Back
Total number of drugs
228
Phase II and later clinical stages
8.3%
Involving companies
271
Main therapeutic areas
Nervous System Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Florquinitau F18 | Florquinitau F18 | Small molecule drug Diagnostic radiopharmaceuticals | Nervous System Diseases Other Diseases | TAU modulators PET imaging | Merck Sharp & Dohme Corp. | Sinotau Pharmaceutical Group University of California Enigma Biomedical Group, Inc. | NDA/BLA | Phase 3 | - | - | - | Fast Track（United States） | - | - | - | - | Florquinitau F18 | - | - | detail > | |
| Flortaucipir F-18 | Flortaucipir F-18 | Small molecule drug Diagnostic radiopharmaceuticals | Nervous System Diseases Other Diseases | TAU modulators | Siemens Healthineers AG | Avid Radiopharmaceuticals, Inc. Eli Lilly Nederland BV PDRadiopharma, Inc. | Approved | - | United States European Union Japan United Kingdom Iceland Liechtenstein Norway | 2020-05-28 | - | - | - | - | - | - | Flortaucipir F-18 | - | - | detail > | |
| Alzheimer's disease vaccine(Axon Biochemicals BV) | Alzheimer's disease vaccine(Axon Biochemicals BV) | Therapeutic vaccine Genetically engineered subunit vaccine Conjugated vaccine | Nervous System Diseases Eye Diseases Other Diseases Endocrinology and Metabolic Disease | TAU modulators Immunostimulants | Axon Biochemicals BV | AXON Neuroscience SE | Phase 2 | - | - | - | - | - | - | - | - | - | Alzheimer's disease vaccine(Axon Biochemicals BV) | - | - | detail > | |
| PBT-434 | PBT-434 | Small molecule drug | Nervous System Diseases Endocrinology and Metabolic Disease Other Diseases Congenital Disorders | TAU inhibitors α-synuclein inhibitors | Alterity Therapeutics Ltd. | Alterity Therapeutics Ltd. | Phase 2 | - | - | - | - | Fast Track（United States） Orphan Drug（European Union） Orphan Drug（United States） | - | - | - | - | PBT-434 | - | - | detail > | |
| MK-2214 | MK-2214 | Monoclonal antibody | Nervous System Diseases Other Diseases | TAU inhibitors | Merck & Co., Inc. | Merck Sharp & Dohme LLC Merck Sharp & Dohme Corp. | Phase 2 | - | - | - | - | - | - | - | - | - | MK-2214 | - | - | detail > | |
| Etalanetug | Etalanetug | Monoclonal antibody | Nervous System Diseases Other Diseases | TAU inhibitors | Eisai Co., Ltd. | Eisai, Inc. Eisai Co., Ltd. | Phase 2/3 | - | - | - | - | Fast Track（United States） | - | - | - | - | Etalanetug | - | - | detail > | |
| [F-18]Flornaptitril | [F-18]Flornaptitril | Small molecule drug Diagnostic radiopharmaceuticals | Nervous System Diseases Other Diseases | APP inhibitors TAU modulators PET imaging | Ceremark Pharma LLC University of California, Los Angeles | Ceremark Pharma LLC | Phase 3 | - | - | - | - | - | - | - | - | - | [F-18]Flornaptitril | - | - | detail > | |
| ASN-90 | ASN-90 | Small molecule drug | Nervous System Diseases Eye Diseases Other Diseases Endocrinology and Metabolic Disease | APP inhibitors OGA inhibitors TAU inhibitors | Asceneuron SA | Ferrer Internacional SA Asceneuron SA Merck Serono SA | Phase 2/3 | - | - | - | - | Orphan Drug（United States） | - | - | - | - | ASN-90 | - | - | detail > | |
| Hydromethylthionine mesylate | Hydromethylthionine mesylate | Small molecule drug | Nervous System Diseases Endocrinology and Metabolic Disease Other Diseases | TAU inhibitors | TauRx Pharmaceuticals Ltd. | TauRx Therapeutics Ltd. TauRx Pharmaceuticals Ltd. | NDA/BLA | Phase 3 | - | - | - | Innovative Licensing and Access Pathway（United Kingdom） Orphan Drug（European Union） Orphan Drug（United States） | - | - | - | - | Hydromethylthionine mesylate | - | - | detail > | |
| [18F]Florzolotau | [18F]Florzolotau | Small molecule drug Diagnostic radiopharmaceuticals | Nervous System Diseases Endocrinology and Metabolic Disease Eye Diseases Other Diseases | TAU modulators | Aprinoia Therapeutics, Inc. | Aprinoia Therapeutics, Inc. Celgene Corp. | Phase 3 | Phase 3 | - | - | - | Fast Track（United States） | - | - | - | - | [18F]Florzolotau | - | - | detail > |
Total 228 data
1
2
3
4
5
6
...
22
23
